• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® EXCLUDER® AAA ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

W. L. GORE & ASSOCIATES, INC. GORE® EXCLUDER® AAA ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT Back to Search Results
Catalog Number PLC141200
Medical Device Problem Code Adverse Event Without Identified Device or Use Problem (2993)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 03/29/2025
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
H6: code c19 - a review of the manufacturing records indicated the lot met all pre-release specifications.H6: code b20 -the device remains implanted and was therefore not available for engineering evaluation by gore.Since it is unknown which device is directly implicated in this complaint, plc181000 / (b)(6) / udi-di (b)(4) ,(b)(6) will be included in the report.According to the gore® excluder® aaa endoprosthesis instructions for use (ifu) state ¿adverse events that may occur and/or require intervention include, but are not limited to surgical cut down, bypass or conversion.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
 
Event or Problem Description
The following was reported to gore: on (b)(6) 2025, the patient underwent an endovascular aortic repair (evar) procedure to treat a dissection in the left distal common iliac artery utilizing a gore® excluder® conformable aaa endoprosthesis, two gore® excluder® aaa endoprosthesis, two gore® viabahn® endoprosthesis with propaten bioactive surface (viabahn® device) and three gore® viabahn® vbx balloon expandable endoprosthesis (vbx stent).Reportedly, patient had a tortuous aortic neck and during initial wire access there was a dissection noted in the visceral segment, this was resolved and covered with the conformable main body graft.The procedure went well with all devices implanted.The viabahn and vbx were in the patient's left external iliac artery and extended up into the contralateral leg then another two vbxs and a viabahn were in the left internal extending up into the same contralateral leg to create parallel stents.At the end of the procedure, it was uncertain but there was a possible type 3 endoleak from the parallel vbx stents that were inserted in the hypogastric and external iliac arteries on the patient's left side.Physician decided to wait and see if the endoleak resolved on its own, or review on the ct at next follow up to confirm exact location of the leak.On (b)(6) 2025, the patient was brought back for an emergent procedure to treat the retrograde dissection from above the trunk ipsilateral leg conformable graft near the renal arteries and up to the left subclavian artery (lsa).It is noted that it was a new dissection that potentially was created during the wire access prior to placement of the gore sheaths at the beginning of the original evar procedure.The dissection and endoleak remained, hence, physician decided to explant all devices that were implanted and did an open surgical repair.The explanted devices were discarded.On (b)(6) 2025, the field sales associate was notified of the explant event.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
GORE® EXCLUDER® AAA ENDOPROSTHESIS
Common Device Name
SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
Manufacturer (Section D)
W. L. GORE & ASSOCIATES, INC.
1505 n. fourth street
flagstaff AZ 86004
Manufacturer (Section G)
MEDICAL PHOENIX 2 B/P
32470 n. north valley parkway
phoenix AZ 85085
Manufacturer Contact
jaskaran parhar
1505 n. fourth street
flagstaff, AZ 86004
9285263030
MDR Report Key21913638
Report Number3007284313-2025-03930
Device Sequence Number9042767
Product Code MIH
UDI-Device Identifier00733132618675
UDI-Public(01)00733132618675(17)271106
Combination Product (Y/N)N
Initial Reporter CountryCA
PMA/510(K) Number
P020004
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2025
Device Explanted Year2025
Serviced by Third Party (Y/N)N
Reporter Type Manufacturer
Report Source Company Representative
Initial Reporter Occupation Physician
Type of Report Initial
Report Date (Section B) 04/25/2025
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Operator of Device Health Professional
Device Catalogue NumberPLC141200
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 03/30/2025
Initial Report FDA Received Date04/25/2025
Was Device Evaluated by Manufacturer? (Y/N) Device Not Returned to Manufacturer
Date Device Manufactured11/07/2024
Is the Device Labeled for Single Use? (Y/N) Yes
Usage of Device Initial
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention; Life Threatening; Hospitalization;
Patient SexUnknown
-
-